MDS with del(5q)
Haematology · 2013–2013
1decision
1medicine
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lenalidomide Initial and continuing treatment of patients with transfusion-dependent myelodysplastic syndrome (MDS) classified as low risk or Intermediate-1 according to… | Mar 2013 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.